{"entity":{"id":"nct04381130","kind":"trial","name":"A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial in pancreatic cancer, run by Everfront Biotech Co., Ltd., not yet recruiting.","summary":"A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer is a phase 1/2, interventional study registered as NCT04381130 by Everfront Biotech Co., Ltd., with a registry enrolment figure of 30 participants, started 2027-04-01 and due to reach its primary completion in 2029-12-31. Interventions recorded: EF-009. Conditions listed: Pancreatic Cancer. Primary outcome: Maximum Tolerated Dose (MTD); Overall survival. Pancreatic eligibility wording from the registry: \"Subject has cytological, histological, or pathological confirmation of pancreatic cancer Note: All histologic subtype(s) of exocrine and endocrine pancreatic cancer are eligible to enroll in the study\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04381130","url":"https://clinicaltrials.gov/study/NCT04381130"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04381130","phase":"1/2","setting":"A Phase I/IIa Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profile of EF-009 in Patients With Pancreatic Cancer","sponsor":"Everfront Biotech Co., Ltd.","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04381130/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}